Predictors of Days Unable to Work Among Genotype 1 Treatment-NaiVE Chronic Hepatitis C Patients: Post-Hoc Analyses of Data From Phase 3 Advance and Illuminate Studies

被引：0
|
作者：
Hernandez, Ning C.
Vera-Llonch, Montserrat
Aggarwal, Jyoti
Donepudi, Mrudula
Younossi, Zobair M.
Goss, Thomas F.
机构：
来源：
GASTROENTEROLOGY | 2012年 / 142卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：S955 / S955
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of Sofosbuvir/Velpatasvir for the treatment of treatment-naive, non-cirrhotic patients with chronic hepatitis C genotype 3 infection: integrated analysis of three phase 3 clinical trials
    Borgia, S. M.
    Jacobson, I. M.
    Gane, E. J.
    Weiland, O.
    Lawitz, E.
    Afdhal, N.
    Cheinquer, N.
    Wolf, J.
    Llewellyn, J.
    Houle, S.
    Troke, P.
    Mertens, M.
    Svarovskaia, E.
    Crans, G.
    Stamm, L. M.
    Shafran, S. D.
    Bourliere, M.
    Feld, J. J.
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 196 - 197
  • [22] Treatment Response and Tolerability to Pegylated Interferon (PEG Inf) and Ribavirin (RBV) in Treatment-Naive Asian American Patients with Chronic Hepatitis C and Genotype 1, 2/3 and 6
    Nguyen, Nghia H.
    Vutien, Philip
    Trinh, Huy N.
    Garcia, Ruel T.
    Wan, Kenton
    Nguyen, Huy A.
    Nguyen, Khanh K.
    Levitt, Brian S.
    Nguyen, Mindie H.
    GASTROENTEROLOGY, 2009, 136 (05) : A791 - A791
  • [23] Efficacy and safety of glecaprevir/pibrentasvir treatment for 8 weeks in treatment-naive patients with chronic hepatitis C virus infection without cirrhosis or with compensated cirrhosis: Analysis of data pooled from phase 2 and 3 studies
    Zuckerman, Eli
    Gutierrez, Julio
    Ustianowski, Andrew
    Naggie, Susanna
    Caruntu, Florin Alexandru
    Ravendhran, Natarajan
    Sigal, Samuel
    Barrett, Lisa
    Cohen, Stanley
    Crown, Eric
    Dylla, Doug
    Fredrick, Linda
    Wang, Stanley
    Porcalla, Ariel
    Mensa, Federico
    Bruno, Savino
    JOURNAL OF HEPATOLOGY, 2019, 70 (01) : E251 - E251
  • [24] EFFICACY AND SAFETY OF GLECAPREVIR/PIBRENTASVIR TREATMENT FOR 8 WEEKS IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION WITHOUT CIRRHOSIS OR WITH COMPENSATED CIRRHOSIS: ANALYSIS OF DATA POOLED FROM PHASE 2 AND 3 STUDIES
    Gutierrez, Julio
    Zuckerman, Eli
    Ustianowski, Andrew
    Naggie, Susanna
    Caruntu, Florin
    Ravendhran, Natarajan
    Sigal, Samuel
    Barrett, Lisa
    Cohen, Stanley M.
    Crown, Eric
    Dylla, Doug
    Fredrick, Linda
    Wang, Stanley
    Porcalla, Ariel R.
    Mensa, Federico
    Bruno, Savino
    GASTROENTEROLOGY, 2019, 156 (06) : S1218 - S1218
  • [25] NO EFFECT OF FALDAPREVIR ON RENAL FUNCTION IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION: POOLED DATA FROM TWO PHASE III TRIALS
    Zeuzem, S.
    Jensen, D. M.
    Carvalho, A.
    Diago, M.
    Feinman, S. V.
    Kowdley, K. V.
    Kao, J. -H.
    Maevskaya, M.
    Negro, F.
    Mantry, P.
    Tanaka, Y.
    Forton, D.
    Genne, D.
    Paik, S. W.
    Zehnter, E.
    Kuboki, M.
    Lee, W. M.
    Peng, C. -Y.
    Yatsuhashi, H.
    Stern, J. O.
    Datsenko, Y.
    Drulak, M.
    Voss, F.
    Boecher, W.
    Ferenci, P.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S451 - S451
  • [26] Subgroup analyses and baseline predictors of response with faldaprevir plus pegylated interferon alfa-2a and ribavirin in treatment-naive patients with chronic hepatitis C genotype-1 infection: A pooled analysis of STARTVerso1 and 2
    Yoshida, Eric M.
    Asselah, Tarik
    Moreno, Christophe
    Maevskaya, Marina V.
    Kao, Jia-Horng
    Crespo, Javier
    Dufour, Jean-Francois
    Wong, David K.
    Tam, Edward
    Feinman, Victor S.
    Schuchmann, Marcus
    Omata, Masao
    Ferenci, Peter
    Kowdley, Kris V.
    Lee, Youn-Jae
    Tomita, Eiichi
    Paik, Seung Woon
    Yatsuhashi, Hiroshi
    Stern, Jerry O.
    Quinson, Anne-Marie
    Voss, Florian
    Scherer, Joe
    Datsenko, Yakov
    Jensen, Donald M.
    HEPATOLOGY, 2013, 58 : 751A - 752A
  • [27] FINAL SVR24 DATA FROM THE PHASE 3 C-EDGE TREATMENT-NAIVE STUDY OF ELBASVIR (EBR)/GRAZOPREVIR (GZR) IN PATIENTS WITH CHRONIC HCV GENOTYPE 1, 4 OR 6 INFECTION
    Zeuzem, S.
    Ghalib, R.
    Reddy, K. R.
    Pockros, P.
    Ari, Z. B.
    Zhao, Y.
    Brown, D.
    DiNubile, M.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Butterton, J.
    Martin, E.
    JOURNAL OF HEPATOLOGY, 2016, 64 : S821 - S821
  • [28] ASUNAPREVIR (ASV; BMS-650032), AN NS3 PROTEASE INHIBITOR, IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C INFECTION
    Bronowicki, J-P
    Pol, S.
    Thuluvath, P.
    Larrey, D.
    Martorell, C. T.
    Rustgi, V. K.
    Morris, D. W.
    Younes, Z.
    Fried, M. W.
    Bourliere, M.
    Hezode, C.
    Reddy, R.
    Massoud, O.
    Abrams, G. A.
    Ratziu, V.
    He, B.
    Eley, T.
    Ahmad, A.
    Thiry, A.
    Llamoso, C.
    Mendez, P.
    Hughes, E.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S431 - S432
  • [29] Better Work Productivity and Activity in Patients on Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin (3D+RBV or 3D) in Treatment-Naive Adults with Genotype 1(GT1) Chronic Hepatitis C
    Liu, Yan
    Luo, Yan
    Liu, Xuan
    Sullivan, Danielle
    Juday, Timothy R.
    Conway, Brian
    HEPATOLOGY, 2015, 62 : 802A - 802A
  • [30] Final SVR24 data from the phase 3 C-EDGE treatment-naive (TN) study of elbasvir (EBR)/grazoprevir (GZR) in patients with chronic HCV genotype 1, 4 or 6 infection
    Nicoll, A.
    Zeuzem, S.
    Ghalib, R.
    Reddy, K. R.
    Pockros, P. J.
    Ben Ari, Z.
    Wan, S.
    Brown, D.
    Dinubile, M.
    Robertson, M.
    Wahl, J.
    Barr, E.
    Butterton, J.
    Martin, E.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 80 - 80
12345